A 10-year clinical experience with intermittent hormonal therapy for prostate cancer

European Urology

Volumn 43, Issue 3, 2003, Pages 233-240

  Prapotnich, Dominique ^a   Fizazi, Karim ^b   Escudier, Bernard ^b   Mombet, Annick ^a   Cathala, Nathalie ^a   Vallancien, Guy ^a   Gleave, M ^c  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c NONE

Author keywords

Androgen blockade; Castration; Intermittent therapy; Neoplasms metastasis; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE;

ADULT; AGED; ANASTOMOSIS; BLADDER CATHETERIZATION; BONE PAIN; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG INTERMITTENT THERAPY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; ULTRASOUND THERAPY; URINE RETENTION;

EID: 12244271448     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00004-6     Document Type: Conference Paper

References (40)

1. C. Huggins C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293 297
2. L. Denis G.P. Murphy Overview over phase III trials on combined androgen treatment in patients with metastatic prostate cancer Cancer 72 Suppl 1993 3888 3895
3. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265–9.
4. M. Laufer S.R. Denmeade V.J. Sinibaldi M.A. Carducci M.A. Eisenberger Complete androgen blockade for prostate cancer: what went wrong? J. Urol. 164 2000 3 9
5. H.W. Daniell Osteoporosis due to androgen deprivation therapy in men with prostate cancer Urology 58 2 Suppl 1 2001 101 107
6. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235–46.
7. M. Bolla L. Collette L. Blank P. Warde J.B. Dubois R.O. Mirimanoff Long-term results with immediate androgen suppression and external irradiation with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 9327 2002 103 106
8. E.M. Messing J. Manola M. Sarosdy G. Wilding E.D. Crawford D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer New Engl. J. Med. 341 24 1999 1781 1788
9. G.J. Bubley M. Carducci W. Dahut N. Dawson D. Daliani M. Eisenberger Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J. Clin. Oncol. 17 11 1999 3461 3467
10. N. Sato M.E. Gleave N. Bruchovsky P.S. Rennie S.L. Goldenberg P.H. Lange Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model J. Steroid Biochem. Mol. Biol. 58 1996 139 146
11. K.R. Buhler R.A. Santucci R.A. Royai S.C. Whitney R.L. Vessela P.H. Lange Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model Prostate 43 1 2000 63 70
12. K. Akakura N. Bruchovsky P.S. Rennie A.J. Coldman S.L. Goldenberg M. Tenniswood Effects of intermittent androgen suppression on the stem cell composition and the expression of TPRM-2 (clusterin) gene in the shionogi carcinoma J. Steroid Biochem. Mol. Biol. 59 1996 501 511
13. N. Bruchovsky P.S. Rennie A.J. Coldman S.L. Goldenberg M. To D. Lawson Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma Cancer Res. 50 1990 2275 2282
14. R.A. Janknegt C.C. Abbou R. Bartoletti L. Berstein-Hahn B. Bracken J.M. Brisset Orchidectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind trial J. Urol. 149 1993 77 83
15. J.M. Crook E. Szumacher S. Malone S. Huan R. Segal Intermittent androgen suppression in the management of prostate cancer Urology 53 1999 530 534
16. S.L. Goldenberg N. Bruchovsky M.E. Gleave L.D. Sullivan K. Akakura Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 45 1995 839 844
17. C.S. Higano W. Ellis K. Russel P.H. Lange Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Urology 48 1996 800 804
18. A. Sciarra C. Di Chiro F. Di silverio Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer World J. Urol. 18 6 2000 392 400
19. G. Theyer G. Hamilton Current status of intermittent androgen suppression in the treatment of prostate cancer Urology 52 1998 353 359
20. A. Horwich R.A. Huddart J. Gadd P.J. Boyd J.W. Hetherington P. Whelan A pilot study of intermittent androgen deprivation in advanced prostate cancer Br. J. Urol. 81 1998 96 99
21. L.H. Klotz H.W. Herr M.J. Morse W.F. Whitmore Intermittent endocrine therapy for advanced prostate cancer Cancer 58 1986 2546 2550
22. R. Kurek H. Renneberg G. Lübben E. Kienle U.W. Tunn Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer Eur. Urol. 35 1999 27 31
23. G.D. Grossfeld U.B. Chaudary D.M. Reese P.R. Carroll E.J. Small Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer Urology 58 2 2001 240 245
24. J.J. Rambeaud Intermittent complete androgen blockade in metastatic prostate cancer Eur. Urol. 35 1 1999 32 36
25. Zerbib M, Conquy S, Gerbaud PF, Missirliu A, Thioun N, Flam T, et al. Efficacy and effect on quality of life (QOL) of intermittent androgen deprivation for prostate cancer treatment. Eur Urol 1998;33(Suppl 1)[Abstract 354].
26. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235–46.
27. M. Bolla D. Gonzalez P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin New Engl. J. Med. 337 1997 295 300
28. A.V. D’Amico K. Cote M. Loffredo A.A. Renshaw D. Schultz Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 2002 4567 4573
29. D.P. Byar Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate Cancer 32 1973 1126 1130
30. J.T. Isaacs The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer Prostate 5 1984 1 17
31. J.H. Goldie A.J. Coldman A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate Cancer Treat. Rep. 63 1979 1727
32. E.M. Messing J. Manola M. Sarosdy G. Wilding E.D. Crawford D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer New Engl. J. Med. 341 24 1999 1781 1788
33. N. Sato M.E. Gleave N. Bruchovsky S.L. Goldenberg P. Rennie L.D. Sullivan Intermittent androgen suppression delays time to non-androgen regulated prostate specific antigen gene expression in the human prostate LNCaP tumour model J. Steroid Biochem. Mol. Biol. 58 1996 139 146
34. K. Akakura N. Bruchovsky S.L. Goldenberg P.S. Rennie A.R. Buckley L.D. Sullivan Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate specific antigen Cancer 71 1993 2782 2790
35. S.L. Goldenberg N. Bruchovsky M.E. Gleave L.D. Sullivan K. Akakura Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 45 1995 839 845
36. M.E. Gleave N. Bruchovsky S.L. Goldenberg P. Rennie Intermittent androgen suppression: Rationale and clinical experience Eur. Urol. 34 1998 37 41
37. R.T. Oliver G. Williams A.M. Paris J.P. Blandy Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer Urology 49 1997 79 82
38. C.S. Higano W. Ellis K. Russell P.H. Lange Intermittent androgen suppression with leuprolide and flutamide for prostate cancer. A pilot study Urology 48 1996 800 804
39. J.M. Crook E. Szumacher S. Malone Intermittent androgen suppression in the management of prostate cancer Urology 53 1999 530 534
40. N. Bruchovsky L.H. Klotz M. Sadar Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observation Mol. Urol. 4 2000 191 199